natgillin/translations-raw huggingface dataset:
The compositions according to claims 1 to 5, wherein the composition further comprises a reduced level of one or more degradants selected from a group consisting of: and wherein the compositions contain equal to or no more than 0.2% of each impurity on a weight-to-weight of impurity to clevidipine. 
6. Sastav prema zahtjevima od 1 do 5, gdje sastav dalje uključuje smanjeni nivo jednog ili više proizvoda razgradnje izabranih iz grupe koja sadrži: i s
The hinging part comprises a reinforcement rib 70. 
Zglobni dio sadržava rebro za pojačanje 70.
The second stage driving gear of the second stage decelerating device 5 is connected to one end of the second gear shaft 11, and intermeshes with the second stage driven gear in a direction perpendicular to the main shaft 8, the second stage driven gear is connected to one end of the third gear shaft 6, and the other end of the third gear shaft 6 is connected to the bridge gear of the first stage decelerating device 9 . 
Hibridni vozni sustav prema jednom od zahtjeva 1 do 4 i zahtjeva 6, naznačena time da se usporavajući uređaj prvog stupnja (9) sastoji od pogonskih zupčanika prvog stupnja, voznih zupčanika prvog stupnja i mostnih zupčanicika, s time da se pogonski zupčanici spajaju sa mostnim zupčanicima u smjeru okomitom u odnosu na glavnu osovinu (8), mostni zupčanici se spajaju sa voznim zupčanicima prvog stupnja, i vozni zupčanici prvog stupnja su spojeni sa kučištem diferencijala (7).
The biological sample can be any sample containing MON89034 DNA including but not limited to corn oil, corn meal, corn flour, corn gluten, corn cakes, corn starch, corn steep liquor, corn tissue, corn cells, corn grain, corn pollen, corn root tissue, DDGS, and even ethanol produced as a byproduct of fermentation of such transgenic corn so long as the sample contains at least a detectable amount of a polynucleotide diagnostic for the presence of the MON89034 event in the sample. 
(ili) se spomenuta DNA proba obilježava minimalno jednim fluoroforom. Postupak prema zahtjevu 13 ili 15, pri čemu je navedeni biološki uzorak odabran između kukuruznog brašna, kukuruznog ulja, kukuruznih kolača, sjemena kukuruza, klica kukuruza, kukuruznog škroba, kukuruzne peludi, kukuruzne svile, tekućine od namakanja kukuruza, kukuruzne sladi, kukuruznog šećera, kukuruznog sirupa, margarina proizvedenog od kukuruznog ulja, sušenih krutih tvari, kozmetičkih sredstava 1 sredstava za bubrenje.
The material according to any of claims 1-4 wherein the maximum expansion velocity of the intumescent agent is found at temperatures of 180°C or higher and/or the expansion ratio after 30 seconds at 280°C is at least 3:1 (means e.g. 3 mm if the initial thickness had been 1 mm), preferably at least 6:1. 
Materijal u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je najveća brzina ekspanzije bubrivog sredstva na temperaturama od 180 "C ili višim i/ili je omjer ekspanzije nakon 30 sekundi na 280 *€ najmanje 3:1 (znači primjerice 3 mm ako je početna debljina bila 1 mm), po mogućnosti najmanje 6:1.
The method according to claim 16, wherein said disease or condition is diabetic nephropathy, renal failure, glomerulonephritis, nephrotoxicity of aminoglycosides and platinum compounds or hyperactive bladder. 
Derivat pirazolopiridina za upotrebu prema patentnom zahtjevu 13, naznačen time, što je bolest ili poremećaj bubrega izabran iz grupe koju čine dijabetska nefropatija, zastoj rada bubrega, glomerulonefritis, aminoglikozidna nefrotoksičnost, nefrotoksičnost uzrokovana spojevima platine i hiperaktivnost mokraćnog mjehura.
A compound or a pharmaceutically acceptable salt thereof according to claim 1 or a pharmaceutical composition according to any one of claims 2 to 5 for use in a method of treating an HIV infection in a human having or at risk of having the infection. 
Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtevu 1 ili farmaceutski preparat prema bilo kojem od patentnih zahteva od 2 do 5 za upotrebu u postupku tretmana HIV infekcije kod čovjeka koji je inficiran ili kod koga je prisutan rizik infekcije.
The compound according to the invention can also be used together or in combination for simultaneous, separate or sequential use with a gastrin antagonist such as a CCK2 antagonist. 
Spoj prema ovom izumu također se može rabiti skupa ili u kombinaciji za simultanu, odvojenu ili uzastopnu uporabu s antagonistima gastrina poput antagonista CCK2. MEĐUPRODLKTI
The method of claim 1, wherein said parent bacterial strain is selected from Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Rickettsia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, and Oenococcus. 
Postupak prema zahtjevu 1, naznačen time da je navedeni matični bakterijski soj odabran od bakterija Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, = Listeria, - Agrobacterium, = Staphylococcus, = Streptococcus, = Enterococcus, = Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Ricketisia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, te Oenococcus.
in the form of hydrates and all these forms are also within the scope of the present invention. 
u obliku hidrata, a svi navedeni oblici također spadaju u opseg predmetnog izuma.
The method of claim 5 wherein joining is by laser metal forming along the outer edge of the coupon so as create a near final shape joint. 
Postupak prema Zahtjevu 4, gdje se spajanje izvodi laserskim oblikovanjem metala uzduž vanjskog ruba umetka, tako da se dobije spoj približno završenog oblika.
An ODT as claimed in claim 1, wherein the ODT comprises drug particles and rapidly dispersing granules, wherein the drug particles comprise the corticosteroid, and the rapidly dispersing granules comprise the at least one disintegrant and a sugar alcohol and/or saccharide, preferably wherein the drug particles have an average particle size of less than 400 µm, the rapidly dispersing granules have an average particle size of less than 300 µm, and the disintegrant and sugar alcohol and/or saccharide have an average particle size of less than 30 µm; or wherein the corticosteroid is disposed over the surface of an excipient, the rapidly dispersing granules have an average particle size of less than 300 µm, and the disintegrant and sugar alcohol and/or saccharide have an average particle size of less than 30 µm. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 6, naznačeno time da tableta sadrži čestice lijeka i brzo raspršujuće granule, pri čemu čestice lijeka obuhvaćaju budezonid ili njegov solvat ili ester, dok brzo disperzirajuće granule sadrže najmanje jedno sredstvo za razgradnju i šećerni alkohol i/ili saharid. Tableta za oralno disperziranje sukladno patentnom zahtjevu 10, naznačeno time da čestice lijeka imaju prosječne veličinu čestica manje od 400 um, dok brzo raspršujuće granule imaju prosječnu veličinu čestica manje od 300 um, i sredstvo za raspadanje i šećerni alkohol i/ili saharid imaju prosječnu veličinu čestica manju od 30 um; ili pri čemu je budezonid ili njegov solvat ili estar raspoređen po površini ekscipijensa, dok brzo raspršujuće granule imaju prosječnu veličinu čestica manju od 300 um, i sredstvo za raspršivanje i šećerni alkohol i/ili saharid imaju prosječnu veličinu čestica manju od 30 um.
The compound or salt for use according to claim 9, where the solid form has a melting point of 162 to 166 °C, ±3 °C. 
Čvrsti oblik spoja prema patentnom zahtjevu 15 koji ima točku tališta od 162 do 166°C.
determining for the presence of a phosphorylated CHK-1 in a second sample from the test cancer patient who has received a DNA damaging agent and a CHK-1 inhibitor, wherein an increase in the amount of phosphorylated CHK-1 in the second sample compared to the first sample is indicative that the CHK-1 inhibitor is inhibiting its molecular target CHK-1. 
(b) utvrđivanja prisutnosti fosforiliranog CHK-1 u drugom uzorku testiranog pacijenta sa rakom koji je primio agens koji izaziva DNK oštećenje i CHK-I inhibitor, pri čemu je porast u iznosu fosforiliranog CHK-1 u drugom uzorku u odnosu na prvi uzorak indikativan da CHK-1 inhibitor inhibira se svoj molekularni ciljani CHK-1.
Process according to claim 12, characterised in that said resin is a latex and/or acrylate-based binder, said acrylate-based binder preferably being in the form of an aqueous emulsion. Use of at least one ground natural calcium carbonate having a volume median diameter d 50 of between 0.05 and 0.3 µm, in a coating composition having a PVC in the range of from 5 % up to the CPVC and comprising at least one pigment having a refractive index of greater than or equal to 2.5. Use according to claim 14, characterised in that the gloss and/or opacity of the composition is equal to or greater than the gloss and/or opacity of a composition wherein the SMGCC is fully replaced by said pigment having a refractive index of greater than or equal to 2.5. 
Postupak u skladu s patentnim zahtjevom 10 ili 11, karakteriziran na način da je navedena smola lateks i/ili vezivo na bazi akrilata, navedeno vezivo na bazi akrilata je poželjno u obliku vodene emulzije. Uporaba najmanje jednog usitnjenog prirodnog kalcijevog karbonata koji ima d50 (Mal) između 0.05 i 0.3 um, u sastavu za oblaganje koji obuhvaća barem jedan pigment indeksa refrakcije većeg od ili jednakog 2.5, sastava je jednaka ili veća od sjaja i/ili neprozirnosti istog sastava uvođenjem navedenog pigmenta indeksa refrakcije većeg od ili jednakog 2.5 na mjesto navedenog usitnjenog kalcijevog karbonata koji ima d50 između 0.05 10.3 um.
The body support cushion of claim 1, wherein the phase change material includes a plurality of microspheres (54) containing phase change material, and wherein the microspheres (54) are formed in the second layer of viscoelastic foam (18, 118). 
Jastuk za podržavanje tijela u skladu s patentnim zahtjevom 1, naznačen time što materijal promjenjive faze uključuje više mikrosfera (54), koje sadrže materijal promjenjive faze, te što su mikrosfere (54) oblikuje u drugom sloju od viskoclastične pjene (18, 118).
The method according to claim 1, wherein 1 to 6 weight % of solid mineral alkaline in powder form and 0.1 to 5 weight % of concentrated mineral acid are applied, based on the weight of the ammonium nitrate-based particles. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se koristi 1 do 6 % težinskih udjela krute mineralne lužine u praškastom obliku i 0,1 do 5 % težinskih udjela koncentrirane mineralne kiseline, u odnosu na težinu čestica na bazi amonijeva nitrata.
The composition of claims 16 or 17, wherein the carrier comprises hydroxypropyl-B-cyclodextrin in water, and wherein at least about 85% of the compound has a deuterium atom at each position designated as deuterium, and any atom not designated as deuterium is present at about its natural isotopic abundance. 
Tvar iz patentnih zahtjeva 16 ili 17, pri čemu nosač sadrži hidroksipropil-B-ciklodekstrin u vodi i pri čemu najmanje oko 85% tvari ima atom deuterija na svakoj poziciji predviđenoj za deuterij, a svaki je atom koji nije predodređen za deuterij prisutan kao svoj prirodno zastupljeni oblik izotopa.
A method for treating a sleep disorder in a mammal, comprising administering an effective amount of the pharmaceutical composition of claim 1 to the mammal. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 7, i farmakološki prihvatljiv nosač.
A thiazole derivative represented by the formula (IC) or a pharmaceutically acceptable salt thereof for use in the treatment and/or prophylaxis of an anxiety disorder. 
X KAT (ic) ili njegova farmaceutski prihvatljiva sol, pri čemu se on/ona upotrebljava u liječenju i/ili _profilaksi poremećaja anksioznosti.
The smoke evacuator or fire shutter according to claim 6, wherein connecting a battery to the battery connector, triggers the microcontroller to activate of the motor. 
Evakuator dima ili protupožarni kapak prema zahtjevu 5, pri čemu spajanje baterije s priključkom za baterije potiče mikrokontroler da pokrene elektromotor.
The compounds of formulae (I) and (Ia), e.g., the compounds of Examples 1-28, show TRPVI receptor antagonist activity having IC50 values in the range 0.004-30 µM. 
Spojevi formula (1) i (Ia), npr. spojevi iz primjera 1-28, pokazuju djelovanje TRPVI receptor antagonista s vrijednostima ICs5o u rasponu od 0,004 do 30 uM.
Suitably the coupling reaction is carried out in the presence of a suitable base, such as an organic amine, for example di-isopropylethylamine or 4-dimethylaminopyridine. 
Reakcija spajanja se prikladno provodi u prisutnosti baze, poput organskog amina, npr. di-izopropiletilamina ili 4-dimetilaminopiridina.
The use of claim 1 or claim 2, wherein the epothilone D is to be administered orally. 
Uporaba iz patentnog zahtjeva 1 ili 2, pri čemu epotilen D treba davati oralno.
The apparatus of claim 14, further comprising an inversion boot at the outlet of the container, and wherein the inversion boot is tapered to allow the liner to be turned back over the opening and secured thereto. 
Uređaj za sanaciju zračnom inverzijom i parom prema patentnom zahtjevu 18, naznačen time da je spremnik (11) u osnovi pravokutan, a otvor (16) za izlaz inverzijskog kalupa se sužava kako bi omogućio da se materijal za sanaciju okrene unatrag preko otvora i osigura isti.
The method according to claim 20, characterized in that the substrate is coated with a coating formulation of the composition comprising the hedgehog shaped particles, the at least one binder, and the at least one hydrophobizing agent and/or at least one hydrophilizing agent. 
Postupak prema zahtjevu 20, naznačen time da je supstrat presvučen s formulacijom premaza pripravka koji sadrži igličaste čestice, barem jedno vezivno sredstvo, te barem jedno sredstvo za hidrofobiziranje i/ili barem jedno sredstvo za hidrofiliranje.
A vaccine comprising an aqueous composition according to claims 1 to 14. 
Cjepivo koja sadrži vodeni pripravak u skladu sa zahtjevima 1 do 14.
In a fourth aspect of the invention, there is provided the use of a compound according to the invention in its first or second aspects for the manufacture of a medicament for use in the treatment of a condition responsive to inhibition of an enzyme dependent upon folic acid or a folic acid derivative. 
U četvrtom aspektu izuma, donosi se spoj prema izumu u svojem prvom ili drugom aspektu za proizvodnju lijeka za upotrebu u tretiranju stanja koje reagira na inhibiciju enzima ovisnog o folnoj kiselini ili derivatima folne kiseline.
incubating the terpene component with the glucan particle or hollow cell wall particle at atmospheric pressure at a temperature of 20 to 37°C; and 
inkubacija terpenskog sastojka s glukanskom česticom ili česticom šupljih stjenki stanice pod atmosferskim tlakom na temperaturi od 20 do 37°C; te
The position of the container relative to the lid is accurately defined, for example, by the use of the positioning cheeks on the container as described in NL-A 1019526 in the name of the Applicant. 
Smještaj spremnika u odnosu na poklopac je precizno određen, na primjer, korištenjem hvataljki za pozicioniranje na spremniku kao što je opisano u NL-A 1019526 u ime podnositelja.
A composition according to any one of the preceding claims, wherein the amount of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is up to 2.1 mmol, such as selected from the group consisting of up to 2.1 mmol, up to 2 mmol, up to 1.9 mmol, up to 1.8 mmol, up to 1.7 mmol, up to 1.6 mmol, up to 1.5 mmol, up to 1.4 mmol, up to 1.3 mmol, up to 1.2 mmol and up to 1.1 mmol. 
Kompozicija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je količina navedene soli N- (8-(2-hidroksibenzoil)amino)kaprilne kiseline do 2.1 mmol, kao što je izabrana iz grupe koja se sastoji od do 2.1 mmol, do 2 mmol, do 1.9 mmol, do 1.8 mmol, do 1.7 mmol, do 1.6 mmol, do 1.5 mmol, do 1.4 mmol, do 1.3 mmol, do 1.2 mmol 1 do 1.1 mmol.
Analysis of the starting compactin by HPLC using a Waters column RP-18 (5 m, 2.1 x 150 mm) with a mobile phase of (a) 0.1% phosphoric acid and the pH adjusted with 25% NaOH and (b) a mixture of distilled water and acetonitrile (1:9). 
Analiza početnog kompaktina HPLC-om pomoću Waters kolone RP-18 (5m, 2.1 x 150 mm) s mobilnom fazom od (a) 0.1% fosfatne kiseline 1 pH podešenog s 25% NaOH i (b) smjese destilirane vode i acetonitrila (1:9).
with the proviso that when R2 and R3 are both hydrogen, R1 cannot be methyl or hydrogen; 
uz uvjet da kada su R2 i R3 oba vodik, R1 ne može biti metil ili vodik;
The method according to claim 1, wherein the xerostomia is associated with late-stage cancer. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s rakom u kasnoj fazi.
Preferably, the composition further comprises a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Spoj, njegova farmaceutski prihvatljiva sol ili smjesa prema zahtjevu 5, za uporabu u liječenju bolesti ili stanja izabranih između; emocionalna nestabilnost; o pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskinezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropalska bol; bol posredovana simpalikusom; bol povezana s disfunkcijom probavnog suslava; epileptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RTT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom.
A method of preparing a hollow glucan particle or hollow cell wall particle encapsulating a terpene component in accordance with any one of claims 1 to 43, said method comprising the steps of; providing a terpene component; 
Metoda pripremanja šuplje glukanske čestice ili čestice šupljih stjenki stanice koje enkapsuliraju terpenski sastojak, a koja metoda se sastoji od sljedećih koraka: dodavanje terpenskog sastojka koji sadrži geraniol, eugenol ili timol;
preparing a pharmaceutical composition by a process comprising combining the crystalline sodium salt of claim 1, with at least one pharmaceutically acceptable carrier or diluent; and administering to said mammal a therapeutically effective amount of the prepared pharmaceutical composition. 
Farmaceutski sastav, naznačen time, da obuhvaća natrijevu sol prema zahtjevu 1, 2, 3, 4, 5, 6 ii 7 kao 1 farmaceutski prihvatljiv nosač ili razrjeđivač.
the formed insulation block is removed from the mould. 
nastali izolacijski blok se hladi, i -
Device according to any one of the preceding claims 1 to 5, characterised in that said at least one hole (33) has, on the outline wall, at least one guiding or engaging projection (36, 36') protruding towards the inside of the hole (33). 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se navedeno najmanje jedno tijelo koje ima geometriju valjka (4) drži na mjestu unutar najmanje jedne rupe (33) u koraku stavljanja u kalup (5) mehaničkim međudjelovanjem s rupom (33).
Freeze-dried molded article according to any one of the embodiments 1 to 7, with a content of scaffold-forming agents of ≦10% by wt., more preferably ≦5% by wt., in each case based on the total composition of the freeze-dried molded article. 
Liofilizirani oblikovani proizvod sukladno zahtjevu 1 do 3, sa sadržajem agensa za formiranje skeleta < 10% tež., poželjnije < 5 % tež., temeljem ukupnog sastava liofiliziranog oblikovanog proizvoda.
It depends, for example, on the nature and severity of the illness to be treated, on the condition of the patient, on the compound employed or on whether an acute or chronic disease state is treated is conducted or on whether further active compounds are administered in addition to the compounds of the present invention. 
To ovisi, na primjer, o prirodi i jačini oboljenja koje treba tretirati, o stanju pacijenta, o korištenom spoju te o tome je li stanje akutno ili kronično, te provodi li se liječenje ili profilaksa, te koriste li se neki drugi aktivni spojevi kao dodatak spojevima prikazanog izuma.
the composition comprises dextran; 
(vi) farmaceutski sastav obuhvaća dekstran;
The method of claim 1, wherein the indication of the resource set is an offset value, compared to a reference resource set. 
Metoda iz bilo kojeg od prethodnih patentnih zahtjeva, gdje je indikacija skupa resursa,ofset" vrijednost, u usporedbi sa referentnim skupom resursa.
The immunogenic composition of claims 1-4 wherein the carrier protein is selected from the group consisting of: TT, DT, CRM197, fragment C of TT and protein D. The immunogenic composition of claims 1-5 wherein the carrier protein is TT. 
Postupak u skladu s patentnim zahtjevima 1-9, naznačen time što se proteinski nosač bira iz skupine koju čine: TT, DT, CRM197, fragment C od TT, protein D iz bakterije H. influenzae, pneumokokni PhtD, te pneumokokni pneumolizin.
about 400 millibars to about 600 millibars; 
(iv) od oko 400 milibara pa do 600 milibara.
A monoclonal antibody capable of binding to human GDF-15, or an antigen-binding portion thereof, wherein the binding is binding to a conformational or discontinuous epitope on human GDF-15 comprised by the amino acid sequences of SEQ ID No: 25 and SEQ ID No: 26. 
Monoklonsko antitijelo koje se može vezati na humani GDF-15, ili njegov dio koji se veže na antigen, a koji se može vezati za humani GDF-15, pri čemu: i) = varijabilna domena teškog lanca obuhvaća regiju CDR3 koja sadrži sekvencu aminokiselina SEQ ID NO:
Such uses preferably rely on formulations whose characteristics include one or more of the following: biocompatibility, stability under ambient conditions, or under conditions that are as near to ambient conditions as possible, with a shelf life that is as long as possible, and easy reconstitutability to form reconstituted solutions that are as stable under ambient, or near ambient conditions, for as long as possible. 
HR P20070374 T3 oslanjaju na oblike čije karakteristike obuhvaćaju jedno ili više od sljedećeg: biokompatibilnost, stabilnost pod uvjetima okoline ili pod uvjetima koji su bliski uvjetima okoline što je više moguće, sa što dužim rokom trajanja, i laka rekonstitucija pri oblikovanju rekonstruiranih otopina koje su stabilne pod uvjetima okoline ili uvjetima koji su bliski uvjetima okoline stoje dulje moguće.
at least one waterproof membrane made of geosynthetic material, having side edges extending in a longitudinal direction of the waterproof panel; 
najmanje jednu vodonepropusnu membranu (16) izrađenu od geosintetskog materijala, s bočnim rubovima koji se protežu u uzdužnom smjeru ploče (14);